Suzanne J Forrest
Overview
Explore the profile of Suzanne J Forrest including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
237
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Forrest S, Gupta H, Ward A, Li Y, Doan D, Al-Ibraheemi A, et al.
Nat Commun
. 2024 Aug;
15(1):7218.
PMID: 39174503
No abstract available.
2.
Forrest S, Gupta H, Ward A, Li Y, Doan D, Al-Ibraheemi A, et al.
Nat Commun
. 2024 Jul;
15(1):5837.
PMID: 38992034
To inform clinical trial design and real-world precision pediatric oncology practice, we classified diagnoses, assessed the landscape of mutations, and identified genomic variants matching trials in a large unselected institutional...
3.
Groves A, Ward A, Li Y, Lazo de la Vega L, Nag A, Forrest S, et al.
Pediatr Blood Cancer
. 2023 Aug;
70(11):e30643.
PMID: 37596911
Utilization of tumor-only sequencing has expanded in pediatric cancer patients, which can lead to identification of pathogenic variants in genes that may be germline and/or have uncertain relevance to the...
4.
Marinoff A, Spurr L, Fong C, Li Y, Forrest S, Ward A, et al.
JCO Precis Oncol
. 2023 Mar;
7:e2200334.
PMID: 36996377
Purpose: Osteosarcoma risk stratification, on the basis of the presence of metastatic disease at diagnosis and histologic response to chemotherapy, has remained unchanged for four decades, does not include genomic...
5.
Lazo de la Vega L, Comeau H, Sallan S, Al-Ibraheemi A, Gupta H, Li Y, et al.
JCO Precis Oncol
. 2022 Nov;
6():e2200390.
PMID: 36446043
Purpose: Multiple FGFR inhibitors are currently in clinical trials enrolling adults with different solid tumors, while very few enroll pediatric patients. We determined the types and frequency of alterations ()...
6.
Church A, Corson L, Kao P, Imamovic-Tuco A, Reidy D, Doan D, et al.
Nat Med
. 2022 Jun;
28(8):1581-1589.
PMID: 35739269
To evaluate the clinical impact of molecular tumor profiling (MTP) with targeted sequencing panel tests, pediatric patients with extracranial solid tumors were enrolled in a prospective observational cohort study at...
7.
Pinches R, Clinton C, Ward A, Meyer S, Al-Ibraheemi A, Forrest S, et al.
Pediatr Blood Cancer
. 2020 Jul;
67(9):e28326.
PMID: 32667141
Introduction: Tissue from pediatric solid tumors is in high demand for use in high-impact research studies, making the allocation of tissue from an anatomic pathology laboratory challenging. We designed, implemented,...
8.
Forrest S, Al-Ibraheemi A, Doan D, Ward A, Clinton C, Putra J, et al.
Clin Cancer Res
. 2020 Mar;
26(12):2882-2890.
PMID: 32122923
Purpose: Several aggressive pediatric cancers harbor alterations in , including rhabdoid tumors, epithelioid sarcoma, and chordoma. As tumor profiling has become more routine in clinical care, we investigated the relationship...
9.
Forrest S, Geoerger B, Janeway K
Curr Opin Pediatr
. 2017 Dec;
30(1):17-24.
PMID: 29189430
Purpose Of Review: The current review describes recent advances and unique challenges in precision medicine for pediatric cancers and highlights clinical trials assessing the clinical impact of targeted therapy matched...
10.
Finkel R, Crawford T, Swoboda K, Kaufmann P, Juhasz P, Li X, et al.
PLoS One
. 2012 May;
7(4):e35462.
PMID: 22558154
Background: Spinal Muscular Atrophy (SMA) is a neurodegenerative motor neuron disorder resulting from a homozygous mutation of the survival of motor neuron 1 (SMN1) gene. The gene product, SMN protein,...